TrialVaccine2022

Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.

Masaharu Shinkai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.